ePrints

Development of an enzymatic pretargeting strategy for dual-modality imaging

Lookup NU author(s): Dr James KnightORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© The Royal Society of Chemistry 2015.A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability. This journal is

Publication metadata

Author(s): Knight JC, Mosley M, Stratford MRL, Uyeda HT, Benink HA, Cong M, Fan F, Faulkner S, Cornelissen B

Publication type: Article

Publication status: Published

Journal: Chemical Communications

Year: 2015

Volume: 51

Issue: 19

Pages: 4055-4058

Print publication date: 07/03/2015

Online publication date: 04/02/2015

Acceptance date: 03/02/2015

ISSN (print): 1359-7345

ISSN (electronic): 1364-548X

Publisher: Royal Society of Chemistry

URL: https://doi.org/10.1039/c4cc10265g

DOI: 10.1039/c4cc10265g

PubMed id: 25660394

Altmetrics

Share